From Dubai to Bali: How Longevium Is Building a Global Longevity Business

The global longevity industry is evolving, and with it, the ambitions of the entrepreneurs building businesses around preventative healthcare, advanced diagnostics, and personalized medicine. But expanding a healthcare concept internationally requires more than identifying a promising market. It demands the ability to replicate clinical standards, navigate unfamiliar regulatory environments, and establish trust with an entirely new patient base.

For Dr. Ksenia Butova, Founder and CEO of Dubai-based Longevium, these challenges are now central to the company’s next chapter. Having established three clinics in Dubai and built a patient base exceeding 30,000, Longevium is embarking on its first international expansion through a joint venture in Bali, Indonesia.

The move represents a strategic milestone for the business, but it also offers a broader perspective on what it takes to transform a locally successful healthcare concept into an international operation.

For founders contemplating international growth, one of the most consequential decisions is determining whether their business is genuinely ready to scale.

Butova believes the answer lies in operational consistency rather than market enthusiasm.

“For us, the signal was that the model held up as we repeated it,” she explains. “We went abroad only after we’d opened a second and third in Dubai and could see the same standard of care holding across all three, with our patient base past 30,000.”

This approach reflects an important principle for entrepreneurs operating in highly regulated industries: a successful flagship location does not necessarily translate into a scalable business.

“Ask yourself whether your model could survive being repeated without you personally in the room every time,” Butova advises.

By validating its clinical and operational model across multiple locations in Dubai before pursuing international expansion, Longevium sought to establish a foundation that could support growth beyond its original market.

While Dubai served as the company’s testing ground, Bali offers a different commercial proposition.

Already established as an international destination for wellness and lifestyle tourism, the Indonesian island attracts visitors who actively prioritize health and are prepared to invest in it.

According to Butova, this creates an opportunity to introduce more advanced medical services to a market where demand already exists.

“Dubai built our credibility with residents first and medical tourism second; Bali is closer to the reverse,” she explains.

Rather than attempting to generate an entirely new customer base, Longevium is positioning itself within an existing community of health-conscious international visitors.

Central to this strategy is its partnership with Nuanu, a coastal development built around a lifestyle-focused community.

The collaboration brings together Longevium’s medical expertise and Nuanu’s established infrastructure and audience.

“We’re not creating demand from nothing; we’re meeting demand that already exists,” Butova says.

For entrepreneurs evaluating international markets, the distinction is significant. Identifying an attractive destination is only one part of the equation; understanding the existing consumer ecosystem can be equally important.

In healthcare, international expansion presents challenges that extend beyond those faced by conventional consumer businesses. Clinical quality, patient confidence, and continuity of care cannot simply be transferred through branding.

“You can’t franchise trust — you have to engineer for it,” Butova says.

At the heart of Longevium’s operating model is a system in which a single physician oversees each patient’s entire healthcare journey, supported by an AI-powered platform that maintains medical histories and identifies relevant information throughout treatment.

This infrastructure is intended to enable continuity of care across geographical boundaries.

For example, a patient beginning a longevity programme in Dubai could continue their treatment in Bali, with physicians at both locations accessing the same medical information.

“That combination is what travels, not just our name on a door,” Butova explains.

The approach also addresses one of the fundamental challenges facing founder-led businesses: maintaining consistent service standards as operations expand beyond the founder’s direct supervision.

Having started her career as a vascular surgeon and researcher, Butova acknowledges that transitioning into the leadership of an international healthcare business has required an entirely different skill set.

“If a standard only exists because I’m personally supervising it, it isn’t a standard yet, it’s a habit.”

For Longevium, digital infrastructure therefore serves two purposes: supporting patient care and translating the company’s established medical protocols into a repeatable operational framework.

Another important element of Longevium’s international strategy is its decision to enter Bali through a joint venture rather than establish an independently operated branch.

Its partnership with entrepreneur Sergey Solonin, who developed Nuanu, provides access to existing infrastructure, local relationships, and an established community.

“Capital gets you a building. It doesn’t get you a community, and it doesn’t get you the local trust that took years to build in Dubai,” Butova explains.

Under the partnership, Nuanu contributes its premises, infrastructure, and community, while Longevium supplies the medical operating model.

For Butova, the arrangement demonstrates why access to capital should not be the only consideration when evaluating international partnerships.

A partner capable of accelerating market entry, providing local knowledge, and connecting a business to its intended audience can bring advantages that financial investment alone cannot replicate.

While Longevium intends to maintain its core clinical philosophy across locations, Butova emphasizes that replicating a healthcare business internationally does not mean offering identical services in every market.

Different regulatory frameworks require businesses to adapt their treatment offerings and operational processes.

In Bali, the company plans to introduce regenerative therapies and newer medical protocols only after they receive the necessary Indonesian regulatory approvals.

“The clinical philosophy travels completely — one physician per patient, advanced diagnostics, a digital record that follows the patient. What doesn’t travel automatically is the treatment list,” she explains.

The broader lesson extends well beyond healthcare.

For businesses operating across regulated sectors, successful internationalization requires distinguishing between the principles that define a company’s identity and the products or services that must be adapted to local requirements.

As Butova puts it: “Your principles export intact; your product catalogue gets rebuilt market by market.”

Longevium’s expansion also comes against the backdrop of growing investment in longevity medicine and medical tourism.

Citing projections from Grand View Research, Butova points to anticipated annual growth exceeding 15% in longevity therapies and 26% in Asia-Pacific medical tourism through 2030.

For her, these figures indicate that longevity is developing beyond its traditional positioning as a premium wellness offering.

Longevium is seeking to capitalize on this development through investment in medical research and technology.

According to Butova, the company raised US$7 million in 2026 specifically to develop an AI-powered longevity research laboratory at Dubai Science Park, which is scheduled to open in the fourth quarter of the year.

She views this investment as evidence of a broader shift toward developing the research infrastructure needed to support the industry’s growth.

“That’s institutional capital underwriting research infrastructure, not just consumer spending on treatments,” she says.

The distinction matters for entrepreneurs entering the sector. As longevity businesses evolve, opportunities may increasingly extend beyond individual clinics and consumer treatments into technology, research, diagnostics, and integrated healthcare platforms.

Despite its ambitions in Indonesia, Longevium’s international expansion does not signal a shift away from its home market.

The company is also planning an additional clinic in Abu Dhabi alongside its upcoming research facility at Dubai Science Park.

Butova believes Dubai’s combination of patient demand, regulatory infrastructure, and access to specialized talent has provided the conditions necessary to establish and validate the company’s business model before introducing it internationally.

“We built and proved this model across three clinics in Dubai before taking it anywhere else,” she says.

For Longevium, Bali represents the first international test of a model developed in the UAE. Its expansion also illustrates how Dubai-based healthcare businesses are exploring opportunities to export their expertise into markets with established demand for advanced medical services.

With additional domestic investments underway and its first international joint venture taking shape, Butova sees further opportunities ahead.

“Bali is the first time we’ve taken that model outside the UAE, but I don’t expect it to be the last, and I don’t think we’re the last Dubai-built healthcare business this will happen to.”